|
|
Vaccine Detail
|
CpG 7909/PF3512676 |
| Vaccine Information |
- Vaccine Name: CpG 7909/PF3512676
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007595
- Type: Analog peptide
- Status: Research
- Antigen: NY-ESO-1 157-165V
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Analog peptide NY-ESO-1 157-165V in combination with CpG and Montanide to promote the expansion of NY-ESO-1-specific CD8+ T cells in patients with advanced cancer. presence of tumor-induced NY-ESO-1-specific T cells of well-defined clonotypes is critical for the expansion of tumor-reactive NY-ESO-1-specific CD8+ T cells after peptide-based vaccine strategies (Fourcade et al., 2008).
|
| References |
Fourcade et al., 2008: Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(8); 781-791. [PubMed: 18779741].
|
|
